There is continuing local and regional need for high-quality and broadly affordable tools and medicines to effectively diagnose and treat several diseases with high prevalence in emerging markets.
Fyodor’s research and development efforts are focused on this growing need, and envisions a complementary suite of affordable at-home or point-of-need diagnostic and biotherapeutic products that will enable the large scale detection and effective treatment of a variety of leading diseases. Fyodor has focused its initial efforts on the development of novel and practical tools for the diagnosis of febrile illness in home or point-of-need settings.
Fyodor’s flagship product is a Urine Malaria Test (UMT) – the first non-blood one-step test for the diagnosis of clinical malaria in persons with a fever, currently in clinical validation.
A second generation broad-based Urine Malaria Test (UMT-Broad) for the detection of Plasmodium falciparum and P. vivax malaria is currently under development, as well as a urine-based test for Leptospira infection. Both of these projects are supported by recent Phase 1 and Phase 2 SBIR grants awarded to Fyodor by the US National Science Foundation. The addition of these agents, and others in the planning stage, will enable the testing of multiple diseases at once in persons who present with fever.